Dublin, Ireland, November 28th, 2018 – Inflection Biosciences Ltd, a private company developing innovative therapeutics for cancer, today announced that new data on IBL-302, a first in class PIM/PI3k/mTOR kinase inhibitor, will be highlighted in a poster at the 2018 AACR Targeting PI3K/mTOR Signalling conference, to be held November 30 – December 3, 2018 in Boston, MA.
The pre-clinical data was generated through a collaboration between Inflection Biosciences and Trinity College Dublin, led by Dr. Kathy Gately, Clinical Senior Lecturer Thoracic Oncology Research at the Trinity Translational Medicine Institute, St. James’s Hospital Dublin. The collaboration is jointly funded by Enterprise Ireland and Inflection Biosciences Ltd.
The details for the poster presentations are as follows:
Poster Title: Activation of the MACC1/PIM/cMyc axis confers resistance to PI3K/mTOR inhibition in PIK3CA mutant NSCLC
Poster Session: B
Time & Date: 12.00 pm – 2.15 pm; Sunday, December 2, 2018
Presenter: Dr. Kathy Gately
Poster Board No.: B14
Location: Harbor Ballroom 1
About PIM/PI3 kinase inhibitors
The PI3K/AKT pathway is commonly activated in human cancer. Multiple small-molecule inhibitors have been developed to target PI3K/mTOR or AKT kinases, but the efficacy of these drugs is compromised by the stimulation of compensatory signalling pathways. One example of such compensatory pathways is that driven by PIM kinases, which produce parallel oncogenic signals to AKT and mTOR and share several downstream substrates. Therefore, combined inhibition of such activities in a single molecule might have the potential to achieve better clinical efficacy and prevent/suppress resistance in comparison with classical PI3K/AKT/mTOR inhibitors.
About Inflection Biosciences
Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the IBL-300 series (PIM/PI3K/mTOR inhibitors) and IBL-202 (PIM/PI3K inhibitor) selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of treatment resistant solid tumours and haematological malignancies. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com